ClinicalTrials.gg
CompletedNCT04914195Updated Aug 1, 2023

Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer

A Phase 3 interventional study of Leuprolide Acetate 3.75 MG/ML in Advanced Prostate Adenocarcinoma, sponsored by Bharat Serums and Vaccines Limited. Completed at 2 sites in India. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Bharat Serums and Vaccines Limited · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
Male
01

Study summary

This is a Randomized, Active Controlled, Comparative, Open-Label, Multi-Center, Phase 3 clinical study to compare the efficacy, safety, and pharmacokinetics of leuprolide acetate for injection 3.75mg (depot) of two brands (Luprodex and Lucrin) administered in subjects with advanced adenocarcinoma of the prostate.

Approximately 168 subjects (males )of age above 18 years fulfilling the eligibility criteria will be enrolled. The IP will be given as a monthly dose for two cycles on day 0 and day 28.

The pharmacokinetic analysis will be done for 12 patients receiving Luprodex. The primary and secondary outcomes will be captured on days as per protocol. Adverse events will be noted for safety evaluation.

02

Conditions studied

  • Advanced Prostate Adenocarcinoma
03

In context

Lead sponsor

Bharat Serums and Vaccines Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects aged above 18 years.
  2. or cytologically confirmed adenocarcinoma of the prostate at stage T1b-4, Nany, Many in subjects, who would benefit from a GnRH agonist.
  3. Baseline Testosterone of >1.50 ng/mL or >150 ng/dL.
  4. For subjects with radical prostatectomy, an increase of 0.2 ng/mL or 20 ng/dL in PSA from previous test on two consecutive tests. For subjects with prostate irradiation a rise of greater than or equal to 2.0 ng/mL or 200 ng/dL PSA above the nadir.
  5. (ECOG) performance status of 0 to 2 (Appendix 2).
  6. of at least 6 months from screening.
  7. Adequate organ and immune system function
  8. Willing to participate and sign the as per regulatory requirements.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of .
  2. Evidence of spinal cord compression.
  3. Evidence of urinary tract obstruction, where a flare in disease could put subject at significant risk in the opinion of the Investigator.
  4. Received prostate cancer therapies like immunotherapy (antibody therapies, tumor vaccines), external radiotherapy, brachytherapy, chemotherapy or biological response modifiers (e.g. cytokines) within two months of enrollment.
  5. Undergone any prostate surgery (e.g. transurethral resection of the prostate (TURP), radical prostatectomy) within two weeks of enrollment.
  6. Under the effects of any other hormonal therapy, including anti-androgens for treatment of prostate cancer within three months of baseline.
  7. Received leuprolide (leuprorelin) previously.
  8. Had an orchiectomy, adrenalectomy or hypophysectomy.
  9. Had used any drug, biologic, or device within five half-lives of its physiological action or three months, whichever is longer, before enrollment.
  10. Anticipated to need concomitant hormonal, anti-androgen, radiotherapy, chemotherapy, immunotherapy or surgical therapy for prostate cancer throughout the duration of the study.
  11. Used over-the-counter (OTC) or alternative medical therapies which has an estrogenic or anti-androgenic effect (e.g., Glycyrrhiza, Dehydroepiandrosterone (DHEA), PC-SPES, saw palmetto) within three months prior to enrollment.
  12. Used finasteride, dutasteride, estrogens, megestrol acetate, anti-androgens (Bicalutamide, Flutamide, or Cyproterone), and ketoconazole within three months prior to baseline.
  13. Co-existent or a history of malignancy, with the exception of basal and/or squamous cell carcinomas of the skin.
  14. Uncontrolled congestive heart failure within six months before baseline.
  15. Experienced a myocardial infarction or a coronary vascular procedure (e.g. balloon angioplasty, coronary artery bypass graft surgery) within six months before baseline.
  16. Significant symptomatic cardiovascular disease within six months of baseline.
  17. Experienced venous thrombosis within six months of baseline.
  18. Uncontrolled hypertension (≥160/100 mmHg) or symptomatic hypotension within three months before baseline.
  19. Insulin-dependent diabetes mellitus (Type I diabetes mellitus).
  20. History of drug abuse within six months of baseline.
  21. Serious intercurrent illnesses or diseases (e.g. hematological, renal, hepatic, respiratory, endocrine, psychiatric) that might interfere with the treatment outlined in the protocol.
  22. Receiving anticoagulants or antiplatelet medications and not receiving a stable dose for three months before baseline. Receiving warfarin-derivative anticoagulants with (INR) outside therapeutic range for the clinical indication for which the anticoagulant has been prescribed.
  23. Known to GnRH, GnRH agonists or any of Leuprolide (leuprorelin).
  24. Positive test for , , HbsAg at Screening.
  25. History of:

    1. Immunization within four weeks of baseline
    2. Flu shots within two weeks of baseline
    3. Donation or receipt of blood or blood products within two months of baseline
    4. Anaphylaxis
    5. Skin disease which would interfere with injection site evaluation
    6. Dermatographism (Physical urticaria).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Leuprolide acetate 3.75 mg Depot (Luprodex)

    Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29

    Drug: Leuprolide Acetate 3.75 MG/ML

  • Active comparator
    Leuprolide acetate 3.75 mg Depot (Lucrin)

    Will be administered subcutaneously once a month for two cycles, on day 0 and on day 28/29

    Drug: Leuprolide Acetate 3.75 MG/ML

Interventions

  • DrugLeuprolide Acetate 3.75 MG/ML

    Drug page: Leuprolide

    Leuprolide Acetate/ Leuprorelin is a depot injection administered as a subcutaneous injection once every month.

06

What researchers measure

Primary outcomes

  1. Testosterone response rate defined as Testosterone values sustained below castration level (0.5 ng/mL or 50 ng/dL) i.e. all Testosterone values at and after Day 28 until Day 57 must be < 0.5 ng/mL or < 50 ng/dL

    Time frame: From Day 28 to day 57

Secondary outcomes

  1. Percentage of subjects who have reached castration level of Testosterone at the last visit (Day 57)

    Time frame: Day 57

  2. Percentage of breakthrough responses defined as a single total serum Testosterone value of >0.5 ng/mL or >50 ng/dL measured after achieving a castration Testosterone level

    Time frame: from Day 28 to Day 57

  3. Time after first implantation until castration level of Testosterone is achieved

    Time frame: up to Day 28

  4. Percentage of subjects with Testosterone values sustained below 0.2 ng/mL or 20 ng/dL at and after Day 28 until Day 57

    Time frame: From Day 28 to Day 57

  5. Change from baseline in Luteinizing hormone (LH) levels at Day 28 and 57

    Time frame: from baseline to Day 28 and from baseline to Day 57

  6. Change from baseline in Follicle Stimulating Hormone (FSH) levels at Day 28 and Day 57

    Time frame: from baseline to Day 28 and from baseline to Day 57

  7. Change from baseline in Prostate-specific antigen (PSA) at Day 57

    Time frame: Day 57

  8. Mean number of days of maintaining testosterone castration levels (mean number of castration days)

    Time frame: day 28 to day 57

  9. Mean maximum testosterone concentration during the dosing period after reaching the castration level

    Time frame: Day 28 to Day 57

07

Study locations

2 sites
  • Government Med ical College & Superspeciality Hospital Nagpur
    Nagpur, Maharashtra 440009, India
  • MV hospital and Research Center
    Lucknow, Uttar Pradesh 226003, India
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Sep 2022, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2021
First posted
Jun 4, 2021
StartActual
Jul 1, 2021
Primary completionActual
Sep 29, 2022
CompletionActual
Sep 29, 2022
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04914195
Lead sponsor
Bharat Serums and Vaccines Limited
Responsible party
Sponsor
First posted
Jun 4, 2021
Start date
Jul 1, 2021
Primary completion
Sep 29, 2022
Completion
Sep 29, 2022
Last update
Aug 1, 2023

Study contacts

Anirban Roy Chowdhury
principal investigator · Bharat Serums and Vaccines Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion